Li Lai: The average weight loss of subjects using the weight loss drug "Ritalu Peptide" is 15.3%.

Eli Company's experimental drug "Ritualutide" for the treatment of obesity has shown greater weight loss effects than any other drug currently on the market, highlighting the potential of the drug in the increasingly competitive next-generation therapy competition. Eli Company announced on Thursday that patients taking the highest dose of Ritualutide had an average weight loss of 15.3%. These late-stage trial results were significantly better than the company's previous blockbuster diabetes drug, "Mufengda", trial results. Eli stated that weekly injections of this injectable can lower blood sugar by 1.9% over approximately nine months, a similar effect to "Mufengda" approved in 2022. "Ritualutide" is one of Eli Company's core strategies for the treatment of obesity, with analysts estimating sales could exceed $10.6 billion by 2036.